Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sanofi ( Sanofi Pasteur, a Sanofi Company )
ClinicalTrials.gov Identifier:
NCT00442169
First received: February 27, 2007
Last updated: January 17, 2014
Last verified: January 2014
  Purpose

The purpose of this study is to determine whether a single subcutaneous injection of ChimeriVax-WN02 vaccine is well tolerated, safe and induces protective antibodies against West Nile Disease. The study is divided into two parts; in the first part, a comparison of 3 dose levels of the vaccine will be made, with an inactive control. In the second part, the optimum dose level chosen after the first part will be given to older volunteers.


Condition Intervention Phase
West Nile Fever
Biological: ChimeriVax-WN02 Low Dose
Biological: ChimeriVax-WN02 Medium Dose
Biological: ChimeriVax-WN02 High Dose
Biological: 0.9% Saline solution
Biological: 0.9 % NaCl solution
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Randomized, Double-blind, Placebo Controlled Phase II Trial of the Safety, Tolerability and Immunogenicity of Lyophilized ChimeriVax-WN02 West Nile Vaccine in Healthy Adults

Resource links provided by NLM:


Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Number of Participants With Fourfold or Greater Post-vaccination Titers (Seroconversion). [ Time Frame: Day 28 post-vaccination ] [ Designated as safety issue: No ]
    Seroconversion was defined as a fourfold or greater rise in titer between pre- and post-immunization samples

  • Number of Viremic Participants Post-vaccination [ Time Frame: Day 21 post-vaccination ] [ Designated as safety issue: No ]
    Viremic = detectable level of ≥ 10 plaque-forming units (PFU)/mL

  • Treatment-emergent Adverse Events Reported As Related to Study Treatment in at Least 5% of Participants in Any Active Treatment Group Post-vaccination. [ Time Frame: Days 0 to 28 post-vaccination ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Geometric Mean Titers of Neutralizing Antibody Titers Pre- and Post-vaccination. [ Time Frame: Days 0, 14, and 28 post-vaccination ] [ Designated as safety issue: No ]

Other Outcome Measures:
  • Number of Participants With Positive Immunoglobulin M (IgM) Response Post-vaccination in the As Treat Per-Protocol Population [ Time Frame: Days 14 and 28 post-vaccination ] [ Designated as safety issue: No ]

Enrollment: 208
Study Start Date: December 2005
Study Completion Date: April 2009
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group 1: WN02 Low Dose (Part 1)
Low Dose in healthy adults in Part 1 against a placebo control.
Biological: ChimeriVax-WN02 Low Dose
Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region.
Experimental: Group 2: WN02 Medium Dose (Part 1)
Medium dose level in part one healthy subjects against a placebo control.
Biological: ChimeriVax-WN02 Medium Dose
Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
Experimental: Group 3: WN02 High Dose (Part 1)
High dose level in part one healthy subjects against a placebo control
Biological: ChimeriVax-WN02 High Dose
Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
Placebo Comparator: Group 4: Placebo (Part 1)
Participants will receive a single dose of saline in Part 1 on Day 0
Biological: 0.9% Saline solution
Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
Experimental: Group 5: WNO2 High Dose (Part 2)
Participants enrolled in Part 2 and received a single dose of West Nile Virus vaccine.
Biological: ChimeriVax-WN02 High Dose
Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
Placebo Comparator: Group 6: Placebo (part 2)
Participants will receive a single dose of saline in Part 2 on Day 0
Biological: 0.9 % NaCl solution
Single dose given in a volume of 0.5 mL by subcutaneous injection to the deltoid region

Detailed Description:

West Nile Disease has been carried across the United States by migrating birds since it was first identified in New York city in 1999. It is transmitted by mosquitoes from birds to humans and can cause severe disease in some individuals. There is no specific treatment for West Nile Disease. The target population for a West Nile vaccine is older people, as they are more susceptible to severe disease. This trial includes a dose-finding part with a placebo control in young healthy adults, followed by a placebo-controlled examination of the chosen dose in older healthy adults.

Outcome measures include a comparison of adverse events between active treatment and placebo, a comparison of antibody and viremia measurements between dose levels and across age groups for the dose chosen for Part 2.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria: Part 1

  • Healthy adult aged 18 to 40 years.
  • Women of child-bearing potential should be using hormonal contraception.
  • Subject had to be available for the study duration, including all planned follow-up visits.

Exclusion Criteria: Part 1

  • Previous vaccination against yellow fever or Japanese encephalitis
  • History of flavivirus infection
  • Any abnormalities of immune system, or using drugs that affect the immune system.
  • History of anaphylaxis to foods, bee stings, vaccines or drugs.
  • Receipt of blood or blood products within the preceding 6 months.
  • Receipt of any vaccine in the preceding 30 days
  • Seropositive to hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg) or Human immunodeficiency virus (HIV)
  • Lactation or intended pregnancy in female subjects
  • Previous or current military service with overseas deployment
  • Travel to Mexico or other flavivirus endemic areas in the tropics for periods of four weeks or more in the previous ten years.

Inclusion Criteria: Part 2

  • Aged ≥ 41 years.
  • Subjects had to be in general good health.
  • Unimpaired cognitive performance as assessed by clock drawing test score
  • Subject had to be available for all required study visits, including all planned follow-up visits.
  • Women of child-bearing potential should be using hormonal contraception.

Exclusion Criteria: Part 2

  • Clinically significant abnormalities on the Screening 12-lead electrocardiogram (ECG).
  • An acute or chronic medical condition that, in the opinion of the Investigator, would render vaccination unsafe or would interfere with the evaluation of responses. These conditions included, but were not limited to:

    • History of renal impairment
    • History of significant liver disease or hepatic impairment
    • History of diabetes mellitus (except controlled with diet)
    • An arteriosclerotic event during the 6 months prior to enrollment (including but not limited to myocardial infarction or unstable angina, peripheral bypass surgery for revascularization of an extremity, and transient ischemic attack or stroke)
    • Signs of congestive heart failure at the time of enrollment
    • Angina
  • Subjects with 3 or more of the following:

    • Age over 50 years
    • Hypercholesterolemia, or significantly abnormal lipid profile, based on medical history
    • Any prior history of cardiovascular disease
    • Significant family history of cardiovascular disease in any immediate relative
    • History of significant collagen vascular disease.
  • The unexplained presence of any of the following findings:

    • Any significant episodes of confusion, memory loss, language impairment, other cognitive impairment, or other abnormal behavior if relatively abrupt in onset
    • Clinically significant depression
    • Sudden visual impairment (e.g., loss of vision, double vision)
    • Slurred or abnormal speech
    • Sudden onset of vertigo
    • Focal weakness in any extremity
    • Focal sensory loss in any extremity
    • Impaired balance
    • Impaired gait.
  • Subjects with any diagnosis of dementia or associated concomitant medications (e.g., Aricept) used for treating dementia.
  • Subjects with active or a history of neurologic disease or injury, including, but not limited to: Parkinson's, Guillain Barre, epilepsy (except febrile seizures in youth not treated with medication), cerebrovascular accident, head trauma, or any other neurologic condition thought to impact the integrity of the blood-brain barrier.
  • Subjects taking warfarin, heparin, or with known bleeding disorders.
  • Relative or employee of the study site staff, CRO, or Sponsor participating in this trial.
  • A history of vaccination against yellow fever (YF) or Japanese encephalitis. Previous vaccination was determined by history (interview of subject) and/or by reviewing the subject's vaccination card or other official documentation.
  • History of flavivirus infection (e.g. West Nile [WN], Systemic Lupus Erythematosus [SLE], Japanese encephalitis, dengue fever).
  • History of thymoma, thymic surgery (removal), or myasthenia gravis.
  • Known or suspected immunodeficiency disorder, including leukemia, lymphoma, generalized malignancy, or treatment with immunosuppressive medications, including corticosteroids, alkylating agents, anti-metabolites, or radiation therapy. Low dose steroids (≤ 10 mg prednisone or equivalent, topical or intra articular/bursal/tendon/epidural injections of corticosteroids) did not constitute a reason for exclusion.
  • History of residence in or travel to Mexico or flavivirus endemic areas in the tropics (India, southeast Asia, Central America, Caribbean, or South America) for periods of 4 weeks or more within the last 10 years.
  • Subjects with clinically significant screening laboratory abnormalities and/or those having any of the following:

    • Compromised hematopoietic function defined as a hemoglobin < 10.9 (males) or 9.4 (females) g/dL; lymphocyte count > 3000 mm3; neutrophil count < 1000 mm3; or platelet count < 100,000 mm3.
    • Hepatic dysfunction defined as a bilirubin above upper limit of normal or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 x upper limit of normal.
  • Prior history of anaphylaxis to foods, hymenoptera stings, vaccines, or drugs.
  • Transfusion of blood or treatment with any blood product, including intramuscular or intravenous serum globulin within 6 months of the Screening Visit or anticipated up to Day 28, or intention to donate blood in the 28 days after vaccination.
  • Administration of another vaccine within 30 days preceding the screening visit or anticipated up to Day 28 (these subjects could be rescheduled for vaccination at a later date).
  • Physical examination indicating any clinically significant medical condition.
  • Subjects with body temperature >37.8ºC/100.0ºF or acute illness within 3 days prior to vaccination (subject could be rescheduled).
  • Intention to travel out of the area prior to the study visit on Day 28, such that required study visits would be missed.
  • Seropositive to HCV or HIV or positive for HBsAg.
  • Participation in another clinical trial within 60 days of Screening.
  • Lactation or intended pregnancy in female subjects.
  • History of excessive alcohol consumption, drug abuse, or significant psychiatric illness.
  • Intention to increase normal exercise routine, participate in contact sports or strenuous weight lifting, or to initiate vigorous exercise from Screening until after Day 28.
  • At the time of study or past military service with overseas deployment within 10 years of screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00442169

Locations
United States, Arizona
HOPE Research Institute
Phoenix, Arizona, United States, 85050
United States, Idaho
Idaho Infectious Diseases, PLLC
Idaho Falls, Idaho, United States, 83404
United States, Kansas
PRA International Clinical Pharmacology Center
Lenexa, Kansas, United States, 66219
United States, Missouri
Bio-Kinetic Clinical Applications, Inc.
Springfield, Missouri, United States, 65802
United States, Virginia
The Glennan Centre for Geriatrics and Gerontologyy, EVMS
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
Sanofi Pasteur, a Sanofi Company
Investigators
Study Director: Medical Director Sanofi Pasteur Inc.
  More Information

Additional Information:
No publications provided by Sanofi

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Sanofi ( Sanofi Pasteur, a Sanofi Company )
ClinicalTrials.gov Identifier: NCT00442169     History of Changes
Other Study ID Numbers: H-244-003
Study First Received: February 27, 2007
Results First Received: January 21, 2011
Last Updated: January 17, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Sanofi:
West Nile Disease
Antibody response
Viremia
Safety
Tolerability
Prevention

Additional relevant MeSH terms:
West Nile Fever
Encephalitis, Arbovirus
Arbovirus Infections
Virus Diseases
Encephalitis, Viral
Encephalitis
Central Nervous System Viral Diseases
RNA Virus Infections
Flavivirus Infections
Flaviviridae Infections
Central Nervous System Infections
Central Nervous System Diseases
Nervous System Diseases
Pharmaceutical Solutions
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 27, 2014